return equiti ttm
increas estim iqvia follow second-quart earn releas
wednesday morn quarter result impress better-than-expect
revenu driven three segment better-than-expect ebitda well full-year
revenu ep guidanc also increas result modestli increas
revenu ep target full year overal view result encourag
evid demand stabl strong broader pharma outsourc
iqv second-quart result expect top bottom line
million respect book well expectationsund
quarterli book-to-bil ratio time versu typic estim
net award roughli year-ago level organ revenu growth
solut increas sequenti manag note
point headwind pass-through suggest underli growth segment
expect full-year step organ growth last year
year solut organ growth technolog analyt solut
stabl contract sale medic solut improv sequenti posit
illustr exhibit iqv consolid organ revenu growth
best seen sinc merger complet indic view compani
regain share cro space also gain traction new technolog
increas revenu estim million billion
organ constant currenc also increas ep estim
expect underli organ growth technolog
analyt solut segment previou estim
 solut segment expect organ revenu growth compar
previous slightli higher growth ta particular good news
margin leverag well sinc iqv profit segment thu remain
quit comfort continu gener midteen ep growth maintain
outperform rate view current rel valuat reason
consid improv momentum technolog cro servic
iqvia integr inform technology-en healthcar servic provid annual revenu
base billion form merger quintil im health compani employ
roughli employe oper countri compani world lead provid
pharmaceut sale prescript data leader outsourc drug develop commerci
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
exhibit iqvia estim consolid organ growth present
segment observ expect
technolog analyt solut increas bit organ constant-curr basi quarter compar
target total revenu segment beat model million driven mainli sever smaller
acquisit ad approxim percentag point growth manag commentari suggest better-
than-expect growth driven strong perform compani real world evid new technolog
product oce platform model organ growth
 solut increas organ constant-curr basi quarter target manag
note much smaller pass-through revenuesan artifact convers standardreduc organ
growth basi point compani gener net book-to-bil ratio roughli quarter
month ratio year-over-year backlog growth inclus larg cancel
discuss first-quart call metric give us addit comfort cro gain market
share second quarter strong book suggest higher pace revenu growth abl carri
rest beyond expect organ growth
contract sale medic solut increas constant-curr basi second quarter result
surpass expect million continu sequenti improv first quarter organ growth
segment three year model segment grow organ basi percent
full year busi longer appear deterior asset continu view non-core busi
thu would assum eventu divest
increas consolid revenu estim million billion increas
ebitda estim million billion result chang increas ep estim
valuat stock thought
trade time updat estim trade premium clinic cro peer
group averag multipl time maintain outperform rate given encourag sign
strong book solut better order flow asboth drive revenu acceler
updat model iqvia follow exhibit
xxsourc compani report william blair william blair
exhibit updat iqvia hold incom statement summari
gener administr amort incom includ option beg incom expens tax investe non-controlling interests/minor hedg incom item net incom excl non-recurring item incl option beg averag share outstand averag share outstand analysi gross profit beg beg rate revenu begin excl foreign exchang effect pro forma beg organ pro forma beg incom excl non-recur excl non-recur item incl blair compani estimatesourc compani report william blair compani llc estim import disclosur
